Oral BLEX 404 with azacitidine for higher-risk blood disorders
Part of Blood & lymphatic clinical trials.
This trial studies whether BLEX 404 oral liquid, used along with standard azacitidine treatment, can help people with higher-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML). It’s mainly for people who are starting azacitidine for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 20 or older and can sign consent and follow study instructions
- You have MDS (IPSS intermediate-1, intermediate-2, or high-risk) or CMML diagnosed by their scoring system
- You have not had prior treatment for MDS/CMML, and you will start azacitidine for the first time in this study
- Your health tests show you have enough liver and kidney function to safely take study treatment
- Your energy level is good enough (ECOG 0 to 3)
- If you can become pregnant (or are a partner of someone who can), you must use effective birth control as required
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination treatment for people with myelodysplastic syndrome (MDS), a blood disorder. The drug aims to slow the disease and improve blood counts, and might be an option for patients who haven't responded to other treatments.
This study tests a new drug (PBSS1113) combined with azacitidine for people with certain blood cancers (AML or high-risk MDS). The goal is to see if the combination is safe and effective.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
This trial tests whether adding an experimental drug called bexmarilimab to standard azacitidine can help people newly diagnosed with high-risk MDS. Doctors want to see if the combination works better than azacitidine alone.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Hear when a new Myelodysplastic Syndrome (MDS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.